Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28034361,zeta potential,"The optimized formulation (CC-NLC-Opt) showed particle size (183.5±5.89nm), PDI (0.228±0.13), zeta potential (-28.2±0.99mV), and entrapment efficiency (88.9±3.69%).",Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034361/),m,-,9125,DB00796,Candesartan
,28034361,zeta potential,"The optimized formulation (CC-NLC-Opt) showed particle size (183.5±5.89nm), PDI (0.228±0.13), zeta potential (-28.2±0.99mV), and entrapment efficiency (88.9±3.69%).",Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034361/),m,28.2,9126,DB00796,Candesartan
,28034361,entra,"The optimized formulation (CC-NLC-Opt) showed particle size (183.5±5.89nm), PDI (0.228±0.13), zeta potential (-28.2±0.99mV), and entrapment efficiency (88.9±3.69%).",Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034361/),%,88.9,9127,DB00796,Candesartan
,27129488,particle,"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation was found to be 159 ± 8.1 nm, 0.177 ± 0.043, and -23.7 ± 1.02 mV, respectively.","Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129488/),nm,159,10152,DB00796,Candesartan
,27129488,polydispersity index (PDI),"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation was found to be 159 ± 8.1 nm, 0.177 ± 0.043, and -23.7 ± 1.02 mV, respectively.","Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129488/),mv,0.177,10153,DB00796,Candesartan
,27129488,zeta potential,"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation was found to be 159 ± 8.1 nm, 0.177 ± 0.043, and -23.7 ± 1.02 mV, respectively.","Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129488/),mv,-,10154,DB00796,Candesartan
,27129488,zeta potential,"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation was found to be 159 ± 8.1 nm, 0.177 ± 0.043, and -23.7 ± 1.02 mV, respectively.","Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129488/),mv,23.7,10155,DB00796,Candesartan
,29746726,AUC0-∞,"The geometric mean (ng·h/mL) of the AUC0-∞ for the test and brand was 1595.49 and 1620.54, respectively, and the Cmax (ng/mL) was 160.91 and 160.88, respectively.","Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746726/),[h·ng] / [ml],1595.49,16572,DB00796,Candesartan
,29746726,AUC0-∞,"The geometric mean (ng·h/mL) of the AUC0-∞ for the test and brand was 1595.49 and 1620.54, respectively, and the Cmax (ng/mL) was 160.91 and 160.88, respectively.","Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746726/),[h·ng] / [ml],1620.54,16573,DB00796,Candesartan
,29746726,Cmax,"The geometric mean (ng·h/mL) of the AUC0-∞ for the test and brand was 1595.49 and 1620.54, respectively, and the Cmax (ng/mL) was 160.91 and 160.88, respectively.","Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746726/),[ng] / [ml],160.91,16574,DB00796,Candesartan
,29746726,Cmax,"The geometric mean (ng·h/mL) of the AUC0-∞ for the test and brand was 1595.49 and 1620.54, respectively, and the Cmax (ng/mL) was 160.91 and 160.88, respectively.","Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746726/),[ng] / [ml],160.88,16575,DB00796,Candesartan
,9663812,t1/2,"Candesartan, the active metabolite of candesartan cilexetil, declined from peak concentrations at about 4 h with a t1/2 of about 6 h.",Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663812/),h,6,49843,DB00796,Candesartan
,8767349,Cmax,"The M-I concentration in rat plasma attained a peak (Cmax, 0.280 microgram/ml) 2.3 h (Tmax after dosing and then declined with an apparent half-life (t1/2) of 3.8 h.",Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767349/),[μg] / [ml],0.280,69386,DB00796,Candesartan
,8767349,apparent half-life (t1/2),"The M-I concentration in rat plasma attained a peak (Cmax, 0.280 microgram/ml) 2.3 h (Tmax after dosing and then declined with an apparent half-life (t1/2) of 3.8 h.",Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767349/),h,3.8,69387,DB00796,Candesartan
,8767349,Tmax,"In dogs, Tmax, Cmax, and t1/2 of M-I were 1.3 h, 0.012 microgram/ml, and 4.3 h, respectively.",Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767349/),h,1.3,69388,DB00796,Candesartan
,8767349,Cmax,"In dogs, Tmax, Cmax, and t1/2 of M-I were 1.3 h, 0.012 microgram/ml, and 4.3 h, respectively.",Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767349/),[μg] / [ml],0.012,69389,DB00796,Candesartan
,8767349,t1/2,"In dogs, Tmax, Cmax, and t1/2 of M-I were 1.3 h, 0.012 microgram/ml, and 4.3 h, respectively.",Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767349/),h,4.3,69390,DB00796,Candesartan
,8767349,bioavailabilities,"The bioavailabilities of M-I in rats and dogs were 28 and 5%, respectively.",Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767349/),%,28,69391,DB00796,Candesartan
,8767349,bioavailabilities,"The bioavailabilities of M-I in rats and dogs were 28 and 5%, respectively.",Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767349/),%,5,69392,DB00796,Candesartan
,19090875,response rate,The response rate (SBP and DBP <95th percentile) after 1 year was 53%.,"Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19090875/),%,53,74265,DB00796,Candesartan
,9696961,Cmax,"Following single dose administration on day 1, the mean Cmax was 95.2 ng.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),ng,95.2,74623,DB00796,Candesartan
,9696961,AUC0-infinity,The AUC0-infinity was 909 ng.h.ml-1 in healthy volunteers and 1107 ng.h.ml-1 in patients and the elimination half-life was 9.3 h in healthy volunteers and 12 h in the patients.,Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),[h·ng] / [ml],909,74624,DB00796,Candesartan
,9696961,AUC0-infinity,The AUC0-infinity was 909 ng.h.ml-1 in healthy volunteers and 1107 ng.h.ml-1 in patients and the elimination half-life was 9.3 h in healthy volunteers and 12 h in the patients.,Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),[h·ng] / [ml],1107,74625,DB00796,Candesartan
,9696961,elimination half-life,The AUC0-infinity was 909 ng.h.ml-1 in healthy volunteers and 1107 ng.h.ml-1 in patients and the elimination half-life was 9.3 h in healthy volunteers and 12 h in the patients.,Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),h,9.3,74626,DB00796,Candesartan
,9696961,elimination half-life,The AUC0-infinity was 909 ng.h.ml-1 in healthy volunteers and 1107 ng.h.ml-1 in patients and the elimination half-life was 9.3 h in healthy volunteers and 12 h in the patients.,Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),h,12,74627,DB00796,Candesartan
,9696961,Cmax,"At steady state on day 7, mean Cmax values were similar in both groups (112 vs 116 ng.ml-1); the AUC tau was 880 ng.h.ml-1 in healthy subjects and 1080 ng.h.ml-1 in patients while the elimination half-life was 10 h in healthy subjects and 12 h in the patients with liver impairment.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),[ng] / [ml],112,74628,DB00796,Candesartan
,9696961,Cmax,"At steady state on day 7, mean Cmax values were similar in both groups (112 vs 116 ng.ml-1); the AUC tau was 880 ng.h.ml-1 in healthy subjects and 1080 ng.h.ml-1 in patients while the elimination half-life was 10 h in healthy subjects and 12 h in the patients with liver impairment.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),[ng] / [ml],116,74629,DB00796,Candesartan
,9696961,AUC tau,"At steady state on day 7, mean Cmax values were similar in both groups (112 vs 116 ng.ml-1); the AUC tau was 880 ng.h.ml-1 in healthy subjects and 1080 ng.h.ml-1 in patients while the elimination half-life was 10 h in healthy subjects and 12 h in the patients with liver impairment.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),[h·ng] / [ml],880,74630,DB00796,Candesartan
,9696961,AUC tau,"At steady state on day 7, mean Cmax values were similar in both groups (112 vs 116 ng.ml-1); the AUC tau was 880 ng.h.ml-1 in healthy subjects and 1080 ng.h.ml-1 in patients while the elimination half-life was 10 h in healthy subjects and 12 h in the patients with liver impairment.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),[h·ng] / [ml],1080,74631,DB00796,Candesartan
,9696961,elimination half-life,"At steady state on day 7, mean Cmax values were similar in both groups (112 vs 116 ng.ml-1); the AUC tau was 880 ng.h.ml-1 in healthy subjects and 1080 ng.h.ml-1 in patients while the elimination half-life was 10 h in healthy subjects and 12 h in the patients with liver impairment.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),h,10,74632,DB00796,Candesartan
,9696961,elimination half-life,"At steady state on day 7, mean Cmax values were similar in both groups (112 vs 116 ng.ml-1); the AUC tau was 880 ng.h.ml-1 in healthy subjects and 1080 ng.h.ml-1 in patients while the elimination half-life was 10 h in healthy subjects and 12 h in the patients with liver impairment.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),h,12,74633,DB00796,Candesartan
,9696961,drug accumulation,"A moderate drug accumulation of 20%, which does not require a dose adjustment, was observed following once-daily dosing in both groups.",Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696961/),,20,74634,DB00796,Candesartan
,31915110,flow rate,"Following liquid-liquid extraction of the analytes from plasma, chromatographic separation was accomplished on a Waters Reliant C18 column (4.6 × 250 mm, 5 µm) using ACN-5 mM Sodium acetate buffer (80:20, v/v; pH adjusted to 3.5 with acetic acid) as mobile phase at a flow rate of 0.8 mL/min and wavelength of 234 nm.",Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31915110/),[ml] / [min],0.8,96517,DB00796,Candesartan
above,31915110,Extraction recovery,Extraction recovery observed for both analytes was above 90% as well as reproducible and consistent.,Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31915110/),%,90,96518,DB00796,Candesartan
,34070168,Cmax,"Within 0.5 h after single administration, the Cmax of irbesartan and candesartan in retinal tissue was 251 ± 142 ng/g and 63 ± 39 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],251,121977,DB00796,Candesartan
,34070168,Cmax,"Within 0.5 h after single administration, the Cmax of irbesartan and candesartan in retinal tissue was 251 ± 142 ng/g and 63 ± 39 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],63,121978,DB00796,Candesartan
,34070168,Cmax,"In the vitreous humor, a Cmax of 14 ± 16 ng/g for irbesartan was reached 0.5 h after instillation while Cmax was below 2 ng/g for candesartan.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],14,121979,DB00796,Candesartan
below,34070168,Cmax,"In the vitreous humor, a Cmax of 14 ± 16 ng/g for irbesartan was reached 0.5 h after instillation while Cmax was below 2 ng/g for candesartan.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],2,121980,DB00796,Candesartan
,34070168,Cmean,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],338,121981,DB00796,Candesartan
,34070168,Cmean,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],36,121982,DB00796,Candesartan
,34070168,concentrations,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],13,121983,DB00796,Candesartan
<,34070168,concentrations,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],2,121984,DB00796,Candesartan
,34070168,Cmax,The highest plasma concentrations of both irbesartan (Cmax 5.64 ± 4.08 ng/mL) and candesartan (Cmax 4.32 ± 1.04 ng/mL) were reached 0.5 h (Tmax) after single administration.,Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [ml],5.64,121985,DB00796,Candesartan
,34070168,Cmax,The highest plasma concentrations of both irbesartan (Cmax 5.64 ± 4.08 ng/mL) and candesartan (Cmax 4.32 ± 1.04 ng/mL) were reached 0.5 h (Tmax) after single administration.,Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [ml],4.32,121986,DB00796,Candesartan
,34070168,Tmax,The highest plasma concentrations of both irbesartan (Cmax 5.64 ± 4.08 ng/mL) and candesartan (Cmax 4.32 ± 1.04 ng/mL) were reached 0.5 h (Tmax) after single administration.,Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),h,0.5,121987,DB00796,Candesartan
,21228384,half-life,The half-life of candesartan was 6.8 hours in the rabbit eyes.,Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21228384/),h,6.8,123296,DB00796,Candesartan
,8548019,limit of quantitation,"The limit of quantitation (LOQ), using 0.5 ml of serum, was 2 ng/ml for I, 0.8 ng/ml for II, and 0.5 ng/ml for III.","Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548019/),[ng] / [ml],2,137722,DB00796,Candesartan
,8548019,limit of quantitation,"The limit of quantitation (LOQ), using 0.5 ml of serum, was 2 ng/ml for I, 0.8 ng/ml for II, and 0.5 ng/ml for III.","Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548019/),[ng] / [ml],0.8,137723,DB00796,Candesartan
,8548019,limit of quantitation,"The limit of quantitation (LOQ), using 0.5 ml of serum, was 2 ng/ml for I, 0.8 ng/ml for II, and 0.5 ng/ml for III.","Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548019/),[ng] / [ml],0.5,137724,DB00796,Candesartan
,8548019,LOQ,The LOQ for urine sample was 10 ng/ml for II and III.,"Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548019/),[ng] / [ml],10,137725,DB00796,Candesartan
,23146221,cumulative urinary excretion percentages,"After receiving a single 4 mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.",Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146221/),%,0.41,157409,DB00796,Candesartan
,23146221,cumulative urinary excretion percentages,"After receiving a single 4 mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.",Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146221/),%,6.1,157410,DB00796,Candesartan
,16948800,immunoactivity,Angiotensin immunoactivity in plasma increased to 60 +/- 10 pg mL(-1) during infusion of AngII or infusion of AngIII.,Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin-aldosterone-system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948800/),[pg] / [ml],60,159656,DB00796,Candesartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,60,165770,DB00796,Candesartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,80,165771,DB00796,Candesartan
,9438775,elimination half-life,"Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h).","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),h,11 to 15,165772,DB00796,Candesartan
,25080228,Cmax,"Our findings noticed 1.7-fold increase in oral bioavailability of tablet prepared from naringin with mean Cmax and AUC0-12 h values as 35.81 ± 0.13 μg/mL and 0.14 ± 0.09 μg h/mL, respectively.",Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080228/),[μg] / [ml],35.81,173927,DB00796,Candesartan
,25080228,AUC0-12 h,"Our findings noticed 1.7-fold increase in oral bioavailability of tablet prepared from naringin with mean Cmax and AUC0-12 h values as 35.81 ± 0.13 μg/mL and 0.14 ± 0.09 μg h/mL, respectively.",Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080228/),[h·μg] / [ml],0.14,173928,DB00796,Candesartan
,11825094,Oral bioavailability,Oral bioavailability is low (about 40%) because of incomplete absorption.,Clinical pharmacokinetics of candesartan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),%,40,174627,DB00796,Candesartan
more,11825094,Plasma protein binding,Plasma protein binding in humans is more than 99%.,Clinical pharmacokinetics of candesartan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),%,99,174628,DB00796,Candesartan
,11825094,volume of distribution,The volume of distribution in healthy individuals is 0.13 L/kg.,Clinical pharmacokinetics of candesartan. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),[l] / [kg],0.13,174629,DB00796,Candesartan
,11825094,apparent oral clearance,The apparent oral clearance of candesartan is 0.25 L/h/kg after a single dose in healthy individuals.,Clinical pharmacokinetics of candesartan. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),[l] / [h·kg],0.25,174630,DB00796,Candesartan
,11825094,Oral clearance,Oral clearance (3.4 to 28.4 L/h) is highly variable among patients.,Clinical pharmacokinetics of candesartan. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),[l] / [h],3.4 to 28.4,174631,DB00796,Candesartan
,11825094,terminal elimination half-life,"The terminal elimination half-life remains unclear, but appears to be longer than the currently used range of 4 to 9 hours.",Clinical pharmacokinetics of candesartan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),h,4 to 9,174632,DB00796,Candesartan
,11825094,half-life,A 2-compartment analysis revealed a much longer half-life of 29 hours using data from patients with hypertension.,Clinical pharmacokinetics of candesartan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),h,29,174633,DB00796,Candesartan
,11825094,elimination half-life,"For patients with creatinine clearances of >60 ml/min x 1.73m(2), 30 to 60 ml/min x 1.73m(2) and 15 to 30 ml/min x 1.73m(2), the elimination half-life is 7.1, 10.0 and 15.7 hours, respectively, at a dose of 8 mg/day.",Clinical pharmacokinetics of candesartan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),h,7.1,174634,DB00796,Candesartan
,11825094,elimination half-life,"For patients with creatinine clearances of >60 ml/min x 1.73m(2), 30 to 60 ml/min x 1.73m(2) and 15 to 30 ml/min x 1.73m(2), the elimination half-life is 7.1, 10.0 and 15.7 hours, respectively, at a dose of 8 mg/day.",Clinical pharmacokinetics of candesartan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),h,10.0,174635,DB00796,Candesartan
,11825094,elimination half-life,"For patients with creatinine clearances of >60 ml/min x 1.73m(2), 30 to 60 ml/min x 1.73m(2) and 15 to 30 ml/min x 1.73m(2), the elimination half-life is 7.1, 10.0 and 15.7 hours, respectively, at a dose of 8 mg/day.",Clinical pharmacokinetics of candesartan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),h,15.7,174636,DB00796,Candesartan
,11825094,accumulation factor,"However, at 12 mg/day an accumulation factor of 1.71 was found.",Clinical pharmacokinetics of candesartan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),,1.71,174637,DB00796,Candesartan
up to,11825094,maximum daily dose,"Thus, a maximum daily dose of up to 8mg appears suitable in patients with severe renal dysfunction.",Clinical pharmacokinetics of candesartan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825094/),mg,8,174638,DB00796,Candesartan
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,44,195599,DB00796,Candesartan
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,32.2,195600,DB00796,Candesartan
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,40.5,195601,DB00796,Candesartan
,10383542,metabolic,"The estimated metabolic and intercompartmental clearances were 83 ml min-1 (CV 39%) and 9.9 ml min-1, respectively.",Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383542/),[ml] / [min],83,197796,DB00796,Candesartan
,10383542,intercompartmental clearances,"The estimated metabolic and intercompartmental clearances were 83 ml min-1 (CV 39%) and 9.9 ml min-1, respectively.",Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383542/),[ml] / [min],9.9,197797,DB00796,Candesartan
,23118328,C(max),"Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[ng] / [ml],590.5,198029,DB00796,Candesartan
,23118328,C(max),"Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[ng] / [ml],282.1,198030,DB00796,Candesartan
,23118328,half-life,CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05).,"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),h,3.1,198031,DB00796,Candesartan
,23118328,half-life,CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05).,"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),h,2.3,198032,DB00796,Candesartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],1.07,198033,DB00796,Candesartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],0.48,198034,DB00796,Candesartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],0.35,198035,DB00796,Candesartan
,20175802,area under the concentration curve from 0 to 12 h (AUC(0-12)),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],98,205062,DB00796,Candesartan
,20175802,area under the concentration curve from 0 to 12 h (AUC(0-12)),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],138,205063,DB00796,Candesartan
,20175802,AUC(0-6),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],63,205064,DB00796,Candesartan
,20175802,AUC(0-6),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],96,205065,DB00796,Candesartan
,20175802,AUC ratio,"The AUC ratio of MPA glucuronide (MPAG)/MPA co-administered with telmisartan was higher than that without ARBs, but not significantly (14.2 vs. 9.1).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),,14.2,205066,DB00796,Candesartan
,20175802,AUC ratio,"The AUC ratio of MPA glucuronide (MPAG)/MPA co-administered with telmisartan was higher than that without ARBs, but not significantly (14.2 vs. 9.1).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),,9.1,205067,DB00796,Candesartan
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],84,205068,DB00796,Candesartan
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],15,205069,DB00796,Candesartan
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],2220,205070,DB00796,Candesartan
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],15,205071,DB00796,Candesartan
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],2220,205072,DB00796,Candesartan
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],441,205073,DB00796,Candesartan
,29403738,flow rate,The reconstituted samples were chromatographed on a C18 column by using a 80:20 (v/v) mixture of acetonitrile and 0.1% formic acid as the mobile phase at a flow rate of 0.8 mL/min.,Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403738/),[ml] / [min],0.8,208533,DB00796,Candesartan
,29403738,run time,A run time of 2.7 min for each sample made it possible to analyze more than 300 plasma samples per day.,Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403738/),min,2.7,208534,DB00796,Candesartan
,9476035,clearance,"The population pharmacokinetics of candesartan could be best described by a two-compartment body model, parameterized in terms of clearance (14.1 1.h-1), central volume of distribution (118 1), peripheral volume (272 1) and intercompartmental clearance (15.4 1.h-1).",Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9476035/),[1] / [h],14.1,218734,DB00796,Candesartan
,9476035,central volume of distribution,"The population pharmacokinetics of candesartan could be best described by a two-compartment body model, parameterized in terms of clearance (14.1 1.h-1), central volume of distribution (118 1), peripheral volume (272 1) and intercompartmental clearance (15.4 1.h-1).",Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9476035/),1,118,218735,DB00796,Candesartan
,9476035,peripheral volume,"The population pharmacokinetics of candesartan could be best described by a two-compartment body model, parameterized in terms of clearance (14.1 1.h-1), central volume of distribution (118 1), peripheral volume (272 1) and intercompartmental clearance (15.4 1.h-1).",Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9476035/),1,272,218736,DB00796,Candesartan
,9476035,intercompartmental clearance,"The population pharmacokinetics of candesartan could be best described by a two-compartment body model, parameterized in terms of clearance (14.1 1.h-1), central volume of distribution (118 1), peripheral volume (272 1) and intercompartmental clearance (15.4 1.h-1).",Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9476035/),[1] / [h],15.4,218737,DB00796,Candesartan
,9476035,"cumulation half-life (t1/2, beta)","From these model parameters, a cumulation half-life (t1/2, beta) of 29 h was derived.",Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9476035/),h,29,218738,DB00796,Candesartan
,22651563,run time,"The advantages of the described technique included a single method with a shorter run time (2.5 min), simple extraction technique, LLOQ of 1 ng/ml for CAN and 2 ng/ml for HCTZ and lower sample volume (0.10 ml), which overcomes drawbacks of two single methods for each analyte, such as higher analysis time, LOQ and sample volume, as in previously published methods.",LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22651563/),min,2.5,231161,DB00796,Candesartan
,17535067,maximum plasma concentration,"Following administration of candesartan cilexetil 16mg the maximum plasma concentration of candesartan was 244 +/- 54 mug/L and the area under the concentration-time curve over 24 hours, i.e. one dosing interval (AUC(tau)), was 2767 +/- 1162 mug/L . h.",Candesartan cilexetil in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535067/),[μg] / [l],244,245189,DB00796,Candesartan
,17535067,"area under the concentration-time curve over 24 hours, i.e. one dosing interval (AUC(tau))","Following administration of candesartan cilexetil 16mg the maximum plasma concentration of candesartan was 244 +/- 54 mug/L and the area under the concentration-time curve over 24 hours, i.e. one dosing interval (AUC(tau)), was 2767 +/- 1162 mug/L . h.",Candesartan cilexetil in haemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535067/),[μg] / [h·l],2767,245190,DB00796,Candesartan
,31141832,flow rate,"Adequate separation for both analytes was achieved with a Waters C18 column (250 × 4.6 mm, 5 μm) using acetonitrile-5 mm sodium acetate buffer (70:30, v/v; pH adjusted to 3.5 with acetic acid) as a mobile phase at a flow rate of 1.0 mL/min and wavelength of 254 nm.","A simple, rapid and fully validated HPLC method for simultaneous quantitative bio-analysis of rosuvastatin and candesartan in rat plasma: Application to pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31141832/),[ml] / [min],1.0,246051,DB00796,Candesartan
,32702160,CL/F,The mean CL/F value estimated was 7.6 L/h (1.7-22.6 L/h).,Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702160/),[l] / [h],7.6,250406,DB00796,Candesartan
,24168234,AUC0-8 h,"After oral dosing of pure CAN suspension, the mean AUC0-8 h was found to be 0.14 ± 0.09 μgh/ml which was increased significantly, i.e. 0.52 ± 0.13 μgh/ml with freeze-dried solid dispersions in the presence of naringin (p < 0.01).",Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168234/),[μgh] / [ml],0.14,256821,DB00796,Candesartan
,24168234,AUC0-8 h,"After oral dosing of pure CAN suspension, the mean AUC0-8 h was found to be 0.14 ± 0.09 μgh/ml which was increased significantly, i.e. 0.52 ± 0.13 μgh/ml with freeze-dried solid dispersions in the presence of naringin (p < 0.01).",Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168234/),[μgh] / [ml],0.52,256822,DB00796,Candesartan
,24168234,Cmax,"Similarly, the mean Cmax of pure CAN suspension increased from 35.81 ± 0.13 μg/ml (without naringin) to 112.23 ± 0.13 μg/ml (freeze-dried solid dispersions with naringin) (p < 0.01).",Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168234/),[μg] / [ml],35.81,256823,DB00796,Candesartan
,24168234,Cmax,"Similarly, the mean Cmax of pure CAN suspension increased from 35.81 ± 0.13 μg/ml (without naringin) to 112.23 ± 0.13 μg/ml (freeze-dried solid dispersions with naringin) (p < 0.01).",Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168234/),[μg] / [ml],112.23,256824,DB00796,Candesartan
,23030309,AUC(last),The mean for AUC(last) in the reference and the test drug were 1530.1 ± 434.6 and 1315.7 ± 368.6 ng·h/mL.,Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23030309/),[h·ng] / [ml],1530.1,265601,DB00796,Candesartan
,23030309,AUC(last),The mean for AUC(last) in the reference and the test drug were 1530.1 ± 434.6 and 1315.7 ± 368.6 ng·h/mL.,Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23030309/),[h·ng] / [ml],1315.7,265602,DB00796,Candesartan
,23030309,AUC(inf),The mean for AUC(inf) in the reference and the test drug were 1670.0 ± 454.5 and 1441.2 ± 397.8 ng·h/mL.,Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23030309/),[h·ng] / [ml],1670.0,265603,DB00796,Candesartan
,23030309,AUC(inf),The mean for AUC(inf) in the reference and the test drug were 1670.0 ± 454.5 and 1441.2 ± 397.8 ng·h/mL.,Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23030309/),[h·ng] / [ml],1441.2,265604,DB00796,Candesartan
,23030309,C(max),The mean value for C(max) in the reference and the test drug was 142.6 ± 41.0 and 134.9 ± 41.4 ng/mL.,Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23030309/),[ng] / [ml],142.6,265605,DB00796,Candesartan
,23030309,C(max),The mean value for C(max) in the reference and the test drug was 142.6 ± 41.0 and 134.9 ± 41.4 ng/mL.,Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23030309/),[ng] / [ml],134.9,265606,DB00796,Candesartan
,32523332,bioavailability,Results showed a significant increase in the bioavailability of CC from ~15% to ~48%.,Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32523332/),%,15,268871,DB00796,Candesartan
,32523332,bioavailability,Results showed a significant increase in the bioavailability of CC from ~15% to ~48%.,Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32523332/),%,48,268872,DB00796,Candesartan
,32523332,bioavailability,The bioavailability of CC was significantly improved from ~15% to ~48% when formulated as SDs with PVP K-90 with 1:4 drug:polymer ratio.,Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32523332/),%,15,268873,DB00796,Candesartan
,32523332,bioavailability,The bioavailability of CC was significantly improved from ~15% to ~48% when formulated as SDs with PVP K-90 with 1:4 drug:polymer ratio.,Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32523332/),%,48,268874,DB00796,Candesartan
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,30,271417,DB00796,Candesartan
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,33.5,271418,DB00796,Candesartan
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,32,271419,DB00796,Candesartan
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,8.9 to 80.59,271420,DB00796,Candesartan
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,11 to 69.20,271421,DB00796,Candesartan
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,9 to 101.49,271422,DB00796,Candesartan
,9331000,half-life,"The pharmacokinetics did not change on repeated dosing and, as expected from the half-life of candesartan of approximately 9 h in younger subjects, there was almost no accumulation after repeated once-daily dosing.",Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331000/),h,9,271706,DB00796,Candesartan
,9331000,time to peak candes,The time to peak candesartan concentrations after tablet intake was consistently approximately 4 h at all dose levels.,Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331000/),h,4,271707,DB00796,Candesartan
,9331000,half-life,The half-life of candesartan in the elderly (9-12 h) was somewhat longer than in the younger healthy adult volunteers (approximately 9 h) and no gender-related differences in the disposition of candesartan were observed.,Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331000/),h,9-12,271708,DB00796,Candesartan
,9331000,half-life,The half-life of candesartan in the elderly (9-12 h) was somewhat longer than in the younger healthy adult volunteers (approximately 9 h) and no gender-related differences in the disposition of candesartan were observed.,Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331000/),h,9,271709,DB00796,Candesartan
